Skip to main content
SpringerLink
Log in

Rivastigmine Transdermal Patch

In the Treatment of Dementia of the Alzheimer’s Type

  • Adis Drug Profile
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

  • ▴ The cholinesterase inhibitor rivastigmine is now available as a transdermal patch for use in the treatment of mild to moderate dementia of the Alzheimer’s type.

  • ▴ The transdermal patch gradually releases rivastigmine over the application period. There was less fluctuation between plasma peak and trough rivastigmine concentrations with the patch than with the capsule formulation.

  • ▴ The rivastigmine 9.5 mg/24 hours patch was effective in patients with Alzheimer’s disease, according to the results of a well designed, 24-week trial. A significant improvement in Alzheimer’s Disease Assessment Scale —Cognitive subscale (ADAS-Cog) scores and significantly lower Alzheimer’s Disease Cooperative Study —Clinical Global Impression of Change scores were seen with the rivastigmine 9.5 mg/24 hours patch versus placebo.

  • ▴ In addition, treatment with the rivastigmine 9.5 mg/ 24 hours patch was noninferior to rivastigmine 6mg twice-daily capsules, as assessed by ADAS-Cog scores. Significantly more caregivers of study patients preferred administering the patch formulation of rivastigmine than the capsule formulation.

  • ▴ The rivastigmine 9.5 mg/24 hours patch was generally well tolerated by patients with Alzheimer’s disease. The incidence of adverse events (including nausea and vomiting) in the rivastigmine 9.5 mg/ 24 hours patch group was not significantly different to that in the placebo group. However, several adverse events such as nausea and vomiting occurred in significantly more rivastigmine capsule recipients than in placebo recipients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Rubin CD. The primary care of Alzheimer disease. Am J Med Sci 2006 Dec; 332(6): 314–33

    Article  PubMed  Google Scholar 

  2. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54Suppl. 5: S4–9

    PubMed  CAS  Google Scholar 

  3. Wimo A, Winblad B, Aguero-Torres H, et al. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003 Apr–Jun; 17(2): 63–7

    Article  PubMed  Google Scholar 

  4. Vas CJ, Rajkumar S, Tanyakitpisal P, et al. Alzheimer’s disease: the brain killer [online]. Available from URL: http://www.searo.who.int/LinkFiles/Health_and_Behaviour_alzheimers.pdf [Accessed 2007 May 17]

  5. Fillit H, Cummings J. Practice guidelines for the diagnosis and treatment of Alzheimer’s disease in a managed care setting: part II. Pharmacologic therapy. Alzheimer’s Disease Managed Care Advisory Council. Manag Care Interface 2000 Jan; 13(1): 51–6

    CAS  Google Scholar 

  6. Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy 2000 Jan; 20(1): 1–12

    Article  PubMed  CAS  Google Scholar 

  7. Plosker GL, Keating GM. Management of mild to moderate Alzheimer disease. Dis Manage Health Outcomes 2004; 12(1): 55–72

    Article  CAS  Google Scholar 

  8. Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006 Jul; 14(7): 561–73

    Article  PubMed  Google Scholar 

  9. Johannsen P. Long-term cholinesterase inhibitor treatment of Alzheimer’s disease. CNS Drugs 2004; 18(12): 757–68

    Article  PubMed  CAS  Google Scholar 

  10. Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer’s disease: part II. Treatment. Am Fam Physician 2002 Jun 15; 65(12): 2525–34

    Google Scholar 

  11. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease (amended) [online]. September 2007. Available from URL: http://guidance.nice.org.uk/TAl11/guidance/pdf/English/download.dspx [Accessed 2007 September 27]

  12. European Medicines Agency. Exelon® 1.5,3.0, 4.5 and 6.0 hard capsules: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Exelon/H-169-PI-en.pdf [Accessed 2007 May 10]

  13. Novartis Pharmaceuticals Corporation. Exelon® (rivastigmine tartrate) capsules and oral solution: US prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf [Accessed 2007 May 10]

  14. Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer’s disease: getting on and staying on. Curr Ther Res 2003 Apr; 64(4): 216–35

    Article  CAS  Google Scholar 

  15. Lefèvre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer’s disease patients. Clin Pharmacol Ther. Epub 2007 May 23

  16. Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 2006; 23(5): 357–75

    Article  PubMed  CAS  Google Scholar 

  17. Exelon® 4.6 and 9.5 mg/24 hours trandermal patch: summary of product characteristics. Horsham: Novartis Europharm Limited, 2007.

  18. Novartis Pharmaceuticals Corporation. Exelon® patch (rivastigmine transdermal system): US prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf [Accessed 2007 Aug 7]

  19. Eskander MF, Nagykery NG, Leung EY, et al. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer’s plaques and tangles. Brain Res 2005 Oct 26; 1060(1–2): 144–52

    Article  PubMed  CAS  Google Scholar 

  20. Muhlack S, Przuntek H, Müller T. Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer’s disease. Pharmacopsychiatry 2006 Jan; 39(1): 16–9

    Article  PubMed  CAS  Google Scholar 

  21. Darvesh S, Walsh R, Kumar R, et al. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord 2003; 17(2): 117–26

    Article  PubMed  CAS  Google Scholar 

  22. Rakonczay Z. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer’s disease brain. Acta Biol Hung 2003 Aug; 54(2): 183–9

    Article  PubMed  CAS  Google Scholar 

  23. Greig NH, Utsuki T, Yu QS, et al. A new therapeutic target in Alzheimer’s disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001; 17(3): 159–65

    PubMed  CAS  Google Scholar 

  24. Grossberg GT, Stahelin HB, Messina JC, et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000 Mar; 15(3): 242–7

    Article  PubMed  CAS  Google Scholar 

  25. Lefèvre G, Sedek G, Huang HLA, et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007 Apr; 47(4): 471–8

    Article  PubMed  Google Scholar 

  26. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a trans-dermal patch in Alzheimer’s disease: rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007 May; 22(5): 456–67

    Article  PubMed  Google Scholar 

  27. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease. Int J Geriatr Psychiatry 2007 May; 22(5): 485–91

    Article  PubMed  Google Scholar 

  28. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington,DC: American Psychiatric Association, 1994

    Google Scholar 

  29. Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007 Jul 24; 69Suppl. 1: S14–22

    Article  PubMed  CAS  Google Scholar 

  30. Data on file, Novartis Europharm Ltd, 2007

Download references

Acknowledgements

The manuscript was reviewed by: E. Giacobini, Department of Rehabilitation and Geriatrics, University of Geneva Medical School, Geneva, Switzerland; C. Sadowsky, Premiere Research Institute, Palm Beach Neurology, West Palm Beach, Florida, USA. During the peer review process, the manufacturer of the agent under review was also offered an opportunity to comment on this article. Changes based on any comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Wolters Kluwer Health | Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Lily P. H. Yang & Gillian M. Keating

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Lily P. H. Yang & Gillian M. Keating

Authors
  1. Lily P. H. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lily P. H. Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, L.P.H., Keating, G.M. Rivastigmine Transdermal Patch. CNS Drugs 21, 957–965 (2007). https://doi.org/10.2165/00023210-200721110-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200721110-00007

Keywords

Search

Navigation